SoumenKhatuaMD

Pediatric Hematologic Oncology, Pediatric Neuro-Oncology

Senior Associate Consultant

Dr. Khatua is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 2008 - 2009
Children's National Medical Center Pediatric Hematology/Oncology , 2000 - 2003
Driscoll Children's Hospital/Texas A&M College of MedicineResidency, Pediatrics, 1997 - 2000
University of Illinois College of Medicine at ChicagoFellowship, Pediatric Hematology/Oncology, 1987 - 1987
OtherClass of 1987
Children's Hospital of PhiladelphiaFellowship, Pediatric Neuro-Oncology

Academic Excellence Pediatric Society Meeting, 2020
Best in Category Award Society of Pediatric Neuro Oncology, 2016
Best in Category Award for the Early Phase Clinical Trial International Society of Pediatric Neuro Oncology, 2016
Teaching Award, Department of Pediatrics The University of Texas MD Anderson Cancer Center, 2015
Teaching Attending of the Year Award, Department of Pediatrics The University of Texas MD Anderson Cancer Center, 2014
Apple Card Award/Health Education Week The University of Texas MD Anderson Cancer Center, 2013
Hyundai Hope Grant Primary Children's Medical Center, 2010
Join now to see all

ONC201 in Pediatric H3 K27M Gliomas Start of enrollment: 2018 Jan 29
Active, not recruiting
Phase 1
Roles: Contact

PubMed

The emerging field of viroimmunotherapy for pediatric brain tumors.
Marc Garcia-Moure, Virginia Laspidea, Sumit Gupta, Andrew G Gillard, Soumen Khatua
Neuro-Oncology. 2024-11-04
H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.
Leo F Nonnenbroich, Samantha M Bouchal, Elena Millesi, Julian S Rechberger, Soumen Khatua
Cells. 2024-06-28
3 citations
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Yazmin Odia, Carl Koschmann, Nicholas A Vitanza, Peter de Blank, Dolly Aguilera
Neuro-Oncology. 2024-05-03

American Academy of Pediatrics - AAP
Member
American Association for Cancer Research - AACR
Member
American Society of Hematology - ASH
Member
Children's Oncology Group
Member/CNS Committee Member
Data Safety Monitoring Committee (DSMC)
Member
Phase I Clinical Trials, The University of Texas MD Anderson Cancer Center
Member
Harris County Medical Society
Member
Nationwide Children’s Hospital Data Safety Monitoring Board
External Reviewer of High- Risk Oncology Trials
Novartis Pharmaceuticals Data Safety Monitoring Board
External Reviewer
Pediatric Oncology Experimental Therapeutics Investigators Consortium
Member
Posterior Fossa Society
Member
Society for Neuro-Oncology
Reviewer
Society of Immunotherapy Consortium
Member
Texas Oklahoma Pediatric Neuro-Oncology Consortium (TOPNOC)
Member
United States Department of Defense
Grant Reviewer